SCHEMBL21176210

SCHEMBL21176210

COc1ccccc1N(C=O)C(C)C(=O)C(=O)NC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.43
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
IMPDH2 P12268 2/20 0.38
IMPDH1 P20839 2/20 0.38
POLB P06746 2/20 0.37
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALOX12 P18054 1/20 0.34
PAX8 Q06710 1/20 0.34
TLR9 Q9NR96 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
HTR1A P08908 1/20 0.34
CYP2D6 P10635 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21183522 0.85 L3MBTL1 (0.46) HPGDKMT2AMEN1ALDH1A1LMNA
SCHEMBL19975383 0.85 HPGD (0.37) HPGDKMT2AMEN1L3MBTL1HSD17B10
SCHEMBL19975449 0.83 L3MBTL1 (0.36) HPGDKMT2AMEN1ALDH1A1LMNA
SCHEMBL19974888 0.83 L3MBTL1 (0.36) HPGDKMT2AMEN1ALDH1A1LMNA
SCHEMBL19974891 0.83 L3MBTL1 (0.36) HPGDKMT2AMEN1ALDH1A1LMNA
SCHEMBL19975358 0.83 POLB (0.45) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL19975357 0.83 POLB (0.45) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL19974691 0.82 USP36 (0.36) HPGDKMT2AMEN1ALDH1A1LMNA
SCHEMBL21176236 0.82 MAPK1 (0.40) HPGDKMT2AMEN1POLBALDH1A1
SCHEMBL21183534 0.82 MAPK1 (0.40) HPGDKMT2AMEN1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C HPGD 1205/4885KMT2A 4031/4885MEN1 4331/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C HPGD 1156/4885KMT2A 4177/4885MEN1 4361/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C HPGD 1205/4885KMT2A 4031/4885MEN1 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.